A cancer immunotherapy from CG Oncology delivered into the bladders of patients reduced the risk of tumor recurrence by 68% compared to current medical practice — positive study results announced Monday that may change the way physicians treat certain patients with bladder cancer.
The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors. Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.
The randomized Phase 3 study enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease that is typically removed in a minimally invasive surgical procedure. Patients are then monitored every three months. If the cancer returns, repeat surgical procedures can be performed, but over time, patients lose bladder function and the cancer can continue to grow.

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Source: www.statnews.com



